Latest Cetuximab Stories
Scientists have found a new way to heighten or restore the potency of a widely-used cancer drug.
Scientists at Dana-Farber Cancer Institute and colleagues overseas have discovered a pair of backup circuits in cancer cells that enable the cells to dodge the effect of a widely used cancer drug.
GERMANTOWN, Maryland and HILDEN, Germany, August 5, 2011 /PRNewswire/ -- ? - Food and Drug Administration will review therascreen(R) KRAS RGQ PCR Kit for use with Erbitux(R) (cetuximab), a metastatic colorectal cancer therapy - PMA follows a recent submission for use with another EGFR inhibitor drug, also in patients with metastatic colorectal cancer - QIAGEN achieves milestones in Personalized Healthcare with...
QUEBEC CITY, July 27, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:Â AEZ) (the "Company") today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.
NEW YORK, July 27, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced completion of patient enrollment in its Phase 3 registration trial of KRX-0401 (perifosine) for the treatment of refractory, advanced colorectal cancer.
A study of more than 1,000 patients with colon cancer that had spread to distant sites found that one in eight was treated with at least one drug regimen that was not recommended.
- Growing in low tufty patches.